Syros Pharmaceuticals, Inc.

Syros Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing treatments for hematologic malignancies. Its lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist in Phase III for a genomically defined subset of myelodysplastic syndrome patients and Phase II for acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor in Phase I for select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. It was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.